Literature DB >> 28877607

Levels of Matrix-Degrading Enzymes and Lubricin in Patients With Degenerative Joint Disease Requiring Arthroplasty.

Christopher Wanderling1, Jeffrey Liles1, Elissa Davis2, Daniel Schmitt2, Stephen Statz1, Nil Guler3, Debra Hoppensteadt3, Jawed Fareed3, William Hopkinson2.   

Abstract

Total joint arthroplasty (TJA) of the hip or knee (THA and TKA) is the primary surgical intervention for individuals with degenerative joint disease (DJD). Although it is commonly thought that shear force on the joint causes the degradation of articular cartilage, it is possible that there are other factors that contribute to the progression of DJD. It is plausible that specific enzymes that degrade the joint are upregulated, or conversely, there is downregulation of enzymes critical for joint lubrication. The aim of this study is to profile collagenase-1, elastase, heparanase, and lubricin levels in patients undergoing TJA in order to determine potential preexisting dysregulation that contributes to the pathogenesis of DJD. Deidentified blood samples were obtained from patients undergoing TJA 1 day pre- and 1 day postoperatively. Plasma samples were analyzed using enzyme-linked immunosorbent assay kits for elastase, collagenase-1, heparanase, and lubricin. In comparison to healthy controls, there were significant increases in circulating collagenase-1, elastase, and lubricin levels in both the preoperative and postoperative samples. There were no significant differences in heparanase levels in the preoperative or postoperative samples. Comparing the preoperative versus postoperative patient samples, only lubricin demonstrated a significant change. The results of this study confirm that patients undergoing TJA have preexisting alterations in the levels of matrix-degrading enzymes and lubricin. The alterations observed in this study may provide insight into the pathogenesis of DJD.

Entities:  

Keywords:  MMP; arthroplasty; inflammation; lubricin

Mesh:

Substances:

Year:  2017        PMID: 28877607      PMCID: PMC6709591          DOI: 10.1177/1076029617724231

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  26 in total

Review 1.  Pathophysiology of osteoarthritis.

Authors:  J Martel-Pelletier
Journal:  Osteoarthritis Cartilage       Date:  1998-11       Impact factor: 6.576

2.  Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030.

Authors:  Steven Kurtz; Kevin Ong; Edmund Lau; Fionna Mowat; Michael Halpern
Journal:  J Bone Joint Surg Am       Date:  2007-04       Impact factor: 5.284

3.  Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage.

Authors:  J Martel-Pelletier; M P Faure; R McCollum; F Mineau; J M Cloutier; J P Pelletier
Journal:  J Rheumatol       Date:  1991-12       Impact factor: 4.666

4.  Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: comparison with generalized osteoarthritis.

Authors:  K Naito; M Takahashi; K Kushida; M Suzuki; T Ohishi; M Miura; T Inoue; A Nagano
Journal:  Rheumatology (Oxford)       Date:  1999-06       Impact factor: 7.580

5.  Type III collagen, a fibril network modifier in articular cartilage.

Authors:  Jiann-Jiu Wu; Mary Ann Weis; Lammy S Kim; David R Eyre
Journal:  J Biol Chem       Date:  2010-04-19       Impact factor: 5.157

6.  Mechanisms of disruption of the articular cartilage surface in inflammation. Neutrophil elastase increases availability of collagen type II epitopes for binding with antibody on the surface of articular cartilage.

Authors:  H E Jasin; J D Taurog
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

7.  Sites of collagenase cleavage and denaturation of type II collagen in aging and osteoarthritic articular cartilage and their relationship to the distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13.

Authors:  William Wu; R Clark Billinghurst; Isabelle Pidoux; John Antoniou; David Zukor; Michael Tanzer; A Robin Poole
Journal:  Arthritis Rheum       Date:  2002-08

Review 8.  Hypertrophic differentiation of chondrocytes in osteoarthritis: the developmental aspect of degenerative joint disorders.

Authors:  Rita Dreier
Journal:  Arthritis Res Ther       Date:  2010-09-16       Impact factor: 5.156

9.  Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis.

Authors:  Rachel W Li; Craig Freeman; Di Yu; Elizabeth J Hindmarsh; Kathleen E Tymms; Christopher R Parish; Paul N Smith
Journal:  Arthritis Rheum       Date:  2008-06

Review 10.  Aggrecanases and cartilage matrix degradation.

Authors:  Hideaki Nagase; Masahide Kashiwagi
Journal:  Arthritis Res Ther       Date:  2003-02-14       Impact factor: 5.156

View more
  1 in total

1.  Investigation of synovial fluid lubricants and inflammatory cytokines in the horse: a comparison of recombinant equine interleukin 1 beta-induced synovitis and joint lavage models.

Authors:  Amanda Watkins; Diana Fasanello; Darko Stefanovski; Sydney Schurer; Katherine Caracappa; Albert D'Agostino; Emily Costello; Heather Freer; Alicia Rollins; Claire Read; Jin Su; Marshall Colville; Matthew Paszek; Bettina Wagner; Heidi Reesink
Journal:  BMC Vet Res       Date:  2021-05-12       Impact factor: 2.741

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.